Matthew Maenner is surveillance team lead for the National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.
Matthew Maenner
Surveillance team lead
National Center on Birth Defects and Developmental Disabilities
From this contributor
Q&A with Matthew Maenner: Estimating autism prevalence quickly
A new method to track autism prevalence in 11 U.S. states is twice as fast as the old approach — and yields similar results.
Q&A with Matthew Maenner: Estimating autism prevalence quickly
By
Peter Hess
13 July 2021 | 6 min read
Explore more from The Transmitter
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
Methodological flaw may upend network mapping tool
The lesion network mapping method, used to identify disease-specific brain networks for clinical stimulation, produces a nearly identical network map for any given condition, according to a new study.
By
Angie Voyles Askham
15 January 2026 | 7 min read
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.
Common and rare variants shape distinct genetic architecture of autism in African Americans
Certain gene variants may have greater weight in determining autism likelihood for some populations, a new study shows.
By
Laura Dattaro
15 January 2026 | 5 min read
Bringing African ancestry into cellular neuroscience
Two independent teams in Africa are developing stem cell lines and organoids from local populations to explore neurodevelopmental and neurodegenerative conditions.
Bringing African ancestry into cellular neuroscience
Two independent teams in Africa are developing stem cell lines and organoids from local populations to explore neurodevelopmental and neurodegenerative conditions.
By
Lauren Schenkman
14 January 2026 | 7 min read